GCP
AIM

GSA Capital Partners’s AIM ImmunoTech AIM Stock Holding History

GSA Capital Partners’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-749
Closed -$170K – 1751
2021
Q1 		$170K Buy
749
+578
+338% +$131K 0.03% 939
2020
Q4 		$31K Sell
171
-787
-82% -$157K 0.01% 1147
2020
Q3 		$206K Buy
+958
New +$239K 0.03% 995

Other funds holding AIM

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

GSA Capital Partners's AIM Position: Q2 2021 in Review

GSA Capital Partners sold out of AIM ImmunoTech (AIM) in Q2 2021, closing a stake of 749 shares — an estimated $170K sold.

GSA Capital Partners first reported a position in AIM in Q3 2020 and held it in 3 quarters. The position peaked at $206K in Q3 2020. 35 funds tracked by Wall St. Rank hold AIM as of Q2 2021.

  • GSA Capital Partners reported no remaining AIM ImmunoTech position as of Q2 2021 after selling out during the quarter.
  • GSA Capital Partners sold 749 AIM ImmunoTech shares in Q2 2021, an estimated $170K.
  • GSA Capital Partners first reported a position in AIM ImmunoTech in Q3 2020 and held it in 3 quarters.
  • GSA Capital Partners's AIM ImmunoTech position peaked at $206K in Q3 2020.
  • 35 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2021.

Based on GSA Capital Partners's 13F filing for Q2 2021, filed 5 Aug 2021.